<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491504</url>
  </required_header>
  <id_info>
    <org_study_id>P05073</org_study_id>
    <nct_id>NCT00491504</nct_id>
  </id_info>
  <brief_title>This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Using Subjective and Objective Measures to Evaluate the Clinical Efficacy of Mometasone Furoate Nasal Spray (MFNS) Following Initial and Maintenance Dosing in Subjects With Allergen-Induced Seasonal Allergic Rhinitis (SAR) in an Environmental Exposure Chamber (EEC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Organon and Co</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Organon and Co</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how well mometasone furoate nasal spray (MFNS) works&#xD;
      to relieve SAR symptoms compared to Placebo when symptoms are induced in a chamber setting.&#xD;
      Evaluation will be based on subjects self-assessed nose symptoms. Other areas the study will&#xD;
      evaluate are: 1) changes in eye symptoms (ocular symptom severity score) after dosing 2) how&#xD;
      long MFNS works in relieving the nose (nasal) and eye (ocular) symptoms after 7 daily doses,&#xD;
      3) measurements of nose (nasal) blockage (obstruction), and 4) measurements of the subject's&#xD;
      opinion of the study drugs by asking different questions. This study is could last up to 53&#xD;
      days for some subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Total Nasal Symptom Severity Score (TNSS) at 6 Hours After Dosage Administration on Day 1</measure>
    <time_frame>Baseline and 6 hours following initial dosing</time_frame>
    <description>Value at 6 hours after dosage administration (Day 1) minus value at Baseline. Minimum threshold TNSS response defined as TNSS score ≥6 out of a possible 12 for combined nasal symptoms of congestion, sneezing, rhinorrhea &amp; itching with a score ≥2 for nasal congestion. Rating of the severity of the individual signs/symptoms according to the following scale: 0=None, sign/symptom wasn't present; 1=Mild, sign/symptom was present, but not disturbing; 2=Moderate, sign/symptom definitely present, &amp; disturbing some of the time; 3=Severe: sign/symptom very noticeable &amp; very bothersome most of the time.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Mometasone Furoate Nasal Spray (MFNS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MFNS 200 mcg total dose (2 sprays each nostril)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (2 sprays each nostril)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate Nasal Spray</intervention_name>
    <description>Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)</description>
    <arm_group_label>Mometasone Furoate Nasal Spray (MFNS)</arm_group_label>
    <other_name>SCH 032088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 2 sprays in each nostril</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate and to adhere to dose and visit schedules&#xD;
&#xD;
          -  18 to 65 years, either sex, any race&#xD;
&#xD;
          -  2-year history of SAR, being symptomatic during the last 2 ragweed seasons&#xD;
&#xD;
          -  Skin test positive to short ragweed allergen at screening, or positive within 12&#xD;
             months&#xD;
&#xD;
          -  Women must practice adequate contraception: Females of childbearing potential&#xD;
             (including women who are less than 1 year postmenopausal and women who will be&#xD;
             sexually active during the study) must agree to use a medically accepted method of&#xD;
             contraception or be surgically sterilized prior to screening, while receiving&#xD;
             protocol-specified medication, and for 30 days after stopping the medication. Women&#xD;
             who are postmenopausal for &gt;1 year (ie, women who have experienced 12 consecutive&#xD;
             months of amenorrhea) will be exempted from the use of contraception during the&#xD;
             study.; Acceptable methods of contraception include condoms (male and female) with or&#xD;
             without a spermicidal agent, diaphragm or cervical cap with a spermicidal agent,&#xD;
             medically prescribed intrauterine device (IUD), oral or injectable hormonal&#xD;
             contraceptives, and surgical sterilization (eg, hysterectomy or tubal ligation)&#xD;
&#xD;
          -  Negative pregnancy tests during study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Compromised ability to provide informed consent&#xD;
&#xD;
          -  Nasal abnormalities, including large nasal polyps, and marked septum deviation that&#xD;
             interferes with nasal airflow at screening&#xD;
&#xD;
          -  Recent (within the last 2 weeks) or unhealed nasal septum ulcers, nasal surgery, or&#xD;
             nasal trauma&#xD;
&#xD;
          -  Unstable asthma which cannot be controlled with inhaled short-acting beta-2 agonists&#xD;
&#xD;
          -  Diagnosed with sinusitis within the previous 2 weeks&#xD;
&#xD;
          -  Is initiating or is currently on advanced immunotherapy&#xD;
&#xD;
          -  If on immunotherapy (desensitization therapy), the subject must be stable and should&#xD;
             not receive an increase in dose during the study. Subjects may not receive&#xD;
             desensitization treatment within 24 hours prior to a study visit&#xD;
&#xD;
          -  Is currently on or has been on an antihistamine, decongestant (topical or systemic) or&#xD;
             a nasal inhaled corticosteroid during the 14 days prior to the first priming visit&#xD;
&#xD;
          -  Unable to refrain from regular use of nasal, oral or ocular decongestants, nasal&#xD;
             topical antihistamines, or nasal steroids&#xD;
&#xD;
          -  Failed the designated washout periods for any of the prohibited medications&#xD;
&#xD;
          -  Upper or lower respiratory tract or sinus infection that required antibiotic therapy&#xD;
             or a viral upper or lower respiratory infection within 14 days prior to screening&#xD;
&#xD;
          -  Is allergic to or has sensitivity to the study drug or its excipients&#xD;
&#xD;
          -  Used any investigational product within 30 days before enrollment or any antibodies&#xD;
             for asthma or allergic rhinitis in the past 90 days&#xD;
&#xD;
          -  Subject has Chronic obstructive pulmonary disease, Alcohol abuse, Rhinitis&#xD;
             medicamentosa&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <results_reference>
    <citation>Salapatek AM, Patel P, Gopalan G, Varghese ST. Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am J Rhinol Allergy. 2010 Nov-Dec;24(6):433-8. doi: 10.2500/ajra.2010.24.3548. Epub 2010 Nov 10.</citation>
    <PMID>21067660</PMID>
  </results_reference>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <results_first_submitted>March 11, 2010</results_first_submitted>
  <results_first_submitted_qc>March 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2010</results_first_posted>
  <last_update_submitted>February 7, 2022</last_update_submitted>
  <last_update_submitted_qc>February 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mometasone Furoate Nasal Spray Day 1</title>
          <description>Mometasone Furoate Nasal Spray (MFNS): 2 sprays each nostril (total 200 mcg) for 1 dose</description>
        </group>
        <group group_id="P2">
          <title>Placebo Day 1</title>
          <description>Placebo: 2 sprays each nostril for 1 dose</description>
        </group>
        <group group_id="P3">
          <title>Mometasone Furoate Nasal Spray Day 8</title>
          <description>Mometasone Furoate Nasal Spray (MFNS): 2 sprays each nostril (200 mcg daily) for 7 days</description>
        </group>
        <group group_id="P4">
          <title>Placebo Day 8</title>
          <description>Placebo: 2 sprays each nostril for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77">All subjects who received MFNS only on Day 1</participants>
                <participants group_id="P2" count="78">All subjects who received placebo only on Day 1</participants>
                <participants group_id="P3" count="78">All subjects who received MFNS on Day 1 through Day 7</participants>
                <participants group_id="P4" count="77">All subjects who received placebo on Day 1 through Day 7</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mometasone Furoate Nasal Spray Day 1</title>
          <description>Mometasone Furoate Nasal Spray (MFNS): 2 sprays each nostril (total 200 mcg) for 1 dose</description>
        </group>
        <group group_id="B2">
          <title>Placebo Day 1</title>
          <description>Placebo: 2 sprays each nostril for 1 dose</description>
        </group>
        <group group_id="B3">
          <title>Mometasone Furoate Nasal Spray Day 8</title>
          <description>Mometasone Furoate Nasal Spray (MFNS): 2 sprays each nostril (200 mcg daily) for 7 days</description>
        </group>
        <group group_id="B4">
          <title>Placebo Day 8</title>
          <description>Placebo: 2 sprays each nostril for 7 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="78"/>
            <count group_id="B4" value="77"/>
            <count group_id="B5" value="310"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="11.1"/>
                    <measurement group_id="B2" value="36.3" spread="10.1"/>
                    <measurement group_id="B3" value="36.9" spread="10.2"/>
                    <measurement group_id="B4" value="38.9" spread="11.2"/>
                    <measurement group_id="B5" value="37.6" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Total Nasal Symptom Severity Score (TNSS) at 6 Hours After Dosage Administration on Day 1</title>
        <description>Value at 6 hours after dosage administration (Day 1) minus value at Baseline. Minimum threshold TNSS response defined as TNSS score ≥6 out of a possible 12 for combined nasal symptoms of congestion, sneezing, rhinorrhea &amp; itching with a score ≥2 for nasal congestion. Rating of the severity of the individual signs/symptoms according to the following scale: 0=None, sign/symptom wasn't present; 1=Mild, sign/symptom was present, but not disturbing; 2=Moderate, sign/symptom definitely present, &amp; disturbing some of the time; 3=Severe: sign/symptom very noticeable &amp; very bothersome most of the time.</description>
        <time_frame>Baseline and 6 hours following initial dosing</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Nasal Spray 200 mcg</title>
            <description>All subjects who received 2 sprays each nostril (total 200 mcg) of Mometasone Furoate Nasal Spray (MFNS) on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All subjects who received 2 sprays each nostril of placebo on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Total Nasal Symptom Severity Score (TNSS) at 6 Hours After Dosage Administration on Day 1</title>
          <description>Value at 6 hours after dosage administration (Day 1) minus value at Baseline. Minimum threshold TNSS response defined as TNSS score ≥6 out of a possible 12 for combined nasal symptoms of congestion, sneezing, rhinorrhea &amp; itching with a score ≥2 for nasal congestion. Rating of the severity of the individual signs/symptoms according to the following scale: 0=None, sign/symptom wasn't present; 1=Mild, sign/symptom was present, but not disturbing; 2=Moderate, sign/symptom definitely present, &amp; disturbing some of the time; 3=Severe: sign/symptom very noticeable &amp; very bothersome most of the time.</description>
          <population>Intent to treat population</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="0.23"/>
                    <measurement group_id="O2" value="-1.86" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.625</p_value>
            <method>ANCOVA</method>
            <method_desc>An analysis of covariance (ANCOVA) model was used with treatment as effect and Baseline as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mometasone Furoate Nasal Spray Day 1</title>
          <description>Mometasone Furoate Nasal Spray (MFNS): 2 sprays each nostril (total 200 mcg) for 1 dose</description>
        </group>
        <group group_id="E2">
          <title>Placebo Day 1</title>
          <description>Placebo: 2 sprays each nostril for 1 dose</description>
        </group>
        <group group_id="E3">
          <title>Mometasone Furoate Nasal Spray Day 8</title>
          <description>Mometasone Furoate Nasal Spray (MFNS): 2 sprays each nostril (200 mcg daily) for 7 days</description>
        </group>
        <group group_id="E4">
          <title>Placebo Day 8</title>
          <description>Placebo: 2 sprays each nostril for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and sponsor's represnetatives will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

